Updated as of May 1, 2018
1. Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US 2. Patients with intermediate or high-risk myelofibrosis 3. Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. European rights to Iclusig licensed from ARIAD 5. In collaboration with AstraZeneca 6. In collaboration with Merck 7. Co-development with Calithera 8. In collaboration with MacroGenics 9. Discovery alliance with Agenus 10.Worldwide rights to baricitinib licensed to Lilly: Approved as Olumiant in multiple territories globally (ex-US) for certain patients with moderate to severe rheumatoid arthritis; NDA re-submitted to FDA in US 11.Worldwide rights to capmatinib licensed to Novartis
We currently have a number of clinical trials underway in oncology. Incyte-sponsored studies and investigator-sponsored trials can be found at www.IncyteClinicalTrials.com.
Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please contact us at ist.incyte.com.
Learn more about our target molecules currently in clinical development>
For Investigator Initiated Research (IIR) conducted outside of the US, please complete your submission at iir.incyte.com.
For questions about Investigator Initiated Research (IIR) conducted outside of the US, please contact Incyte at Global_IIR@incyte.com.